1 / 1

MAb

RESEARCH AND REALITY. ARV-Based Prevention Pipeline (December 2013). PRE-CLINICAL. PHASE I. PHASE II. PHASE III. PHASE IV. MAb. GRF. MVA. TFV/FTC. MVA. TFV Rectal Use. DAP. TFV. TDF/FTC. ACTIVE DRUG. Maraviroc. TMC 278. MIV 150. Tenofovir disoproxil fumarate/emtricitabine.

pepper
Download Presentation

MAb

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. RESEARCH AND REALITY ARV-Based Prevention Pipeline (December 2013) PRE-CLINICAL PHASE I PHASE II PHASE III PHASE IV MAb GRF MVA TFV/FTC MVA TFV Rectal Use DAP TFV TDF/FTC ACTIVE DRUG Maraviroc TMC 278 MIV 150 Tenofovir disoproxil fumarate/emtricitabine TDF DAP 744 MAb TFV GRF MVA DAP MIV 150 TDF TFV TDF/FTC TFV/FTC DELIVERY SYSTEM Tenofovir/ emtricitabine Vaginal film Ripilvirine TFV DAP/MVA GRF TMC 278 MIV 150 Vaginal gel Griffithsin Oral pills TFV 744 Tenofovir Tenofovir disoproxil fumarate Long acting injectable MAb MIV 150 Dapivirine Vaginal tablet GSK 744 For up-to-date information on the ARV-based prevention pipeline, visit the HIV Prevention Research Database at www.avac.org/pxrd. Vaginal ring Monoclonal antibody

More Related